Genome-wide association studies (GWAS) in coronary artery disease (CAD) had identified 66 loci at 'genome-wide significance' (P < 5 × 10 −8 ) at the time of this analysis, but a much larger number of putative loci at a false discovery rate (FDR) of 5% (refs. 1-4). Here we leverage an interim release of UK Biobank (UKBB) data to evaluate the validity of the FDR approach. We tested a CAD phenotype inclusive of angina (SOFT; n cases = 10,801) as well as a stricter definition without angina (HARD; n cases = 6,482) and selected cases with the former phenotype to conduct a meta-analysis using the two most recent CAD GWAS 2,3 . This approach identified 13 new loci at genome-wide significance, 12 of which were on our previous list of loci meeting the 5% FDR threshold 2 , thus providing strong support that the remaining loci identified by FDR represent genuine signals. The 304 independent variants associated at 5% FDR in this study explain 21.2% of CAD heritability and identify 243 loci that implicate pathways in blood vessel morphogenesis as well as lipid metabolism, nitric oxide signaling and inflammation.
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VOLUME 49 | NUMBER 9 | SEPTEMBER 2017 Nature GeNetics l e t t e r s on the basis of power calculations (Supplementary Table 1 ). We found four variants associated with both the SOFT and HARD phenotypes, one SOFT-only variant, and two HARD-only variants reaching genome-wide significance, all located in known CAD-associated loci (Supplementary Fig. 1) .
We then performed meta-analysis of the UKBB data for each CAD definition with each of the two published data sets ( Supplementary  Fig. 2 ), using an inverse-variance-weighted fixed-effect (IVW-FE) model and double-genomic-control correction (Online Methods). For both the SOFT and HARD definitions, we validated all 66 CAD loci known at the time of analysis (72 independent variants with P < 1.2 × 10 −3 , IVW-FE), with 43 and 37 loci, respectively, reaching genome-wide significance in this study (Fig. 1b and Supplementary  Table 2 ). Outside the known CAD loci (the 1-Mb window centered on each published lead SNP), we found nine new signals (for both the SOFT and HARD definitions) reaching genome-wide significance ( Table 1 and Fig. 2 ). The anticipated increase in power with the SOFT definition (Supplementary Table 1 ) was attenuated by inflation of the λ statistic (median of the resulting chi-squared test statistics divided by the expected median of the chi-squared distribution; Supplementary Table 3) , potentially due to the combination of a larger sample size (or polygenicity) and a less homogeneous phenotype in the SOFT definition. Overall, there was strong concordance between corresponding signals for the SOFT and HARD definitions of CAD ( Fig. 1b and Supplementary Table 4) ; subsequent analyses were undertaken using the meta-analysis results for the SOFT definition.
To look for additional signals beyond the nine that reached genomewide significance (Fig. 2) , we performed an FDR-based analysis and selected 23 signals with suggestive evidence of association at 1% FDR (P < 1.55 × 10 −6 , IVW-FE; Supplementary Table 4) outside known CAD loci, which we validated in an independent sample of up to 4,412 cases and 3,910 controls from German MI Family Studies V and VI and a Greek case-control study (Supplementary Table 5 ). In total, we identified 13 genome-wide significant CAD-associated loci in the combined discovery and replication sample that were new at the time of analysis (Table 1 and Supplementary Table 6 ).
In our recent large-scale GWAS 2 , we reported 162 mainly common variants at an FDR discovery cutoff of 5% showing independent association in conditional analysis using the P joint test in GCTA 7 . Twelve of the 13 new sentinel SNPs were present or had a proxy (r 2 > 0.8) among these 162 variants 2 . We observed a strong linear relationship between association signals for these 162 variants in the earlier 2 and current analyses, with overall greater significance levels in the current meta-analysis (Fig. 3) . As expected, we observed an excess of small P values for this set of variants in the UKBB data alone (Supplementary Fig. 3a) . Monte Carlo simulations show that the expected number of variants replicated in the UKBB data is 56 (95% confidence interval (CI) = 42-69) (Supplementary Fig. 3b ), and we found 58 variants after allowing for multiple testing (q < 0.05). This further confirms the validity of extended lists of associated variants based on FDR criteria. We therefore constructed a new FDR-defined list of association signals by performing an approximate joint association analysis with GCTA software 7 , as described elsewhere 2 , using the 11,427 SNPs associated at 5% FDR. We identified 304 independent variants at P joint < 1 ×10 −4 , clustering in 243 putative CAD loci (Supplementary Table 7 ). The new set of variants associated at 5% FDR had 122 SNPs that overlapped with the old set (75.3%; including proxies at r 2 > 0.8). We then assessed heritability using the set of 304 independent SNPs and obtained a heritability estimate of 21.2%. The contribution to this heritability estimate of the 13 new loci ( Table 1) was 1.03%, whereas the new and known genome-wide significant CAD loci at the time of analysis together explained 8.53% of CAD heritability. To further assess the validity and utility of the 5% FDR set, we tested ability to predict CAD using genetic risk scores (GRSs) based on either the 5% FDR SNPs (GRS1) or only the CAD-associated variants reaching genome-wide significance (GRS2; Online Methods) in an independent sample, EPIC-CVD 8 , comprising 7,910 CAD cases and 12,958 controls. In a model with age and sex, GRS1 increased the C index (the probability of a randomly selected patient who experienced an event having a higher risk score than a patient who had not experienced the event) by 0.25% as compared to GRS2 (Supplementary Table 8 ). GRS1 also improved the point estimates of the hazard ratio as compared to GRS2, mainly in the second (0.9116-0.8314) and fourth (1.0437-1.176) quintiles (Supplementary Fig. 4) .
We then explored the biology of the 13 new genome-wide significant CAD risk loci; Supplementary Figure 5 shows regional association plots. Supplementary Figure 6 provides in silico functional annotation (Online Methods) for each lead variant and its proxies (1000 Genomes). We found compelling evidence to implicate candidate genes ITGB5, TGFB1,PDE5A, ARHGEF26, FN1, CDH13 and HNF1 (details in the Supplementary Note). The risk allele of rs150512726 (proxy for rs142695226; Table 1 ) causes a three-residue deletion within the cytoplasmic tail of integrin subunit β5 (ITGB5), part of a heterodimer that regulates the activation of latent transforming growth factor (TGF)-β1 (refs. 9,10). The intronic variant (rs8108632; Table 9 ). For example, the lead variant rs7678555 ( Table 1 ) was found to be a strong eQTL (P = 8.1 × 10 −13 , linear regression model) for PDE5A only in aorta from patients with CAD (STARNET 13 ; Supplementary Table 9 ), although its regulatory potential was found to be modest using functional prediction tools (Online Methods). PDE5A encodes a cGMP-specific phosphodiesterase that is important for smooth muscle relaxation in the cardiovascular system, where it regulates nitric-oxide-generated cGMP 14 . Furthermore, mining eQTL data in tissues from patients with CAD (STARNET) identified several other instances of expression-associated SNPs (including for TDRKH, FN1 and CDH13; Supplementary Table 9 ) having no effect in tissues from individuals without CAD (GTEx 15 ). One caveat is that sample size differs between STARNET and GTEx for certain tissues. Nonetheless, our observation highlights the need to expand efforts to map regulatory elements in tissues from individuals with the disease.
Other candidate genes fit with emerging data on atherosclerosis mechanisms. For example, a knockout mouse for Arhgef26 on a hyperlipidemic background showed reduced atherosclerosis and plaques with reduced macrophage content 16 . Similarly, FN1 expression is increased in atherosclerotic plaques, and mouse models have demonstrated a causal role for fibronectin 1 in the development and progression of atherosclerosis 17, 18 . Finally, we undertook a phenome scan to assess pleiotropy (Supplementary Table 10 ). Several of the new lead SNPs (or proxies) had robust associations (P < 5 × 10 −8 , meta-analysis) with traditional CAD risk factors such as LDL cholesterol (HNF1A and FN1), blood pressure (PRDM8-FGF5) and body mass index (BMI; SNRPD2).
We next evaluated the broader functional relationships among genes associated with variants (n = 11,427) at 5% FDR. The set of variants at 5% FDR was annotated for eQTL associations that, when present, were mainly found in the atherosclerotic aortic wall (25%) or internal mammary artery (22%) of patients with CAD (STARNET 13 ; Supplementary Table 9 ). In GTEx 15 , eQTLs were mainly found in subcutaneous fat (Supplementary Table 9 and Supplementary Fig. 7 ).
Prior pathway analyses of GWAS-identified CAD loci have highlighted genes involved in lipid metabolism, cellular movement, and processes such as tissue morphology and immune cell trafficking 1 . Analysis of 357 genes selected as the eQTL target and/or nearest gene to a 5% FDR independent variant in this study (n = 304) with the Ingenuity Knowledge Base confirmed the above findings 1 , highlighting cardiovascular system development and function (P = 1.31 × 10 −16 , right-tailed Fisher's exact test (rtFET)) and organismal development (P = 1.31 × 10 −16 , rtFET) and survival (P = 1.52 × 10 −16 , rtFET) as the most significant processes. In addition to canonical pathways related to lipid metabolism, extracellular matrix, inflammation and nitric oxide production, the 357-gene set showed enrichment for angiogenesis and signaling by the proangiogenic growth factor VEGF ( Supplementary Fig. 8 ). We also applied DEPICT 19 with the full distribution of 5% FDR signals (Online Methods) to search for enriched gene sets. Blood vessel development, which includes angiogenesis, was among the top ten (P < 6.67 × 10 −12 , enrichment test 19 ) DEPICT Grouped-GeneSets (GO:0001568; Fig. 4 , Supplementary Fig. 9 and Supplementary Table 11) .
Ingenuity built five networks out of the 357 genes, with the largest three integrating 12 of the new candidate CAD risk genes with 
Genes (nearby)
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Gene desert-KCNE2 table 2 ); KSR2 and ZNF507-LOC400684 reached genome-wide significance under a recessive model 2 . The 11p15_MRVI1-CTR9 locus had discordant results in the CAD 1000 Genomes-imputed GWAS 2 and Exome data set 4 . The lead variant in the Exome data set, rs11042937, was associated with P = 3.21 × 10 −8 ; data shown are from the meta-analysis with the 1000 Genomes-imputed GWAS, as this marker had an imputation info score of 1 (Online Methods). The 13 new CAD-associated loci that reached genome-wide significance in our study (including replication data; Table 12 ).
In total, the five networks comprised 66.4% of the 357 genes. This large CAD genetic study simultaneously assesses common, rare (minor allele frequency (MAF) < 1%) and low-frequency (MAF = 1-5%) variants. In total, 101 low-frequency and 3 rare variants reached genome-wide significance among all markers associated at 5% FDR (n = 11,427). This apparent paucity of rare variants, which has also been reported for type 2 diabetes 20 , is likely due to lack of power as compared to studies of quantitative traits. For example, a study of adult height in ~700,000 individuals has reported 32 rare variants 5 . As expected, lower-frequency variants tended to have stronger effects than common variants (Supplementary Fig. 10) , with the exception of rs2891168 in CDK2NB-AS1 (MAF = 48.7%; odds ratio (OR) = 1.19; Supplementary Table 13 ). The intergenic variant rs186696265, which had the largest OR (1.62) in our study, is known to affect LDL cholesterol levels 21 .
Our findings highlight the importance of the FDR approach in defining an extended list of associated variants. As we have previously proposed 1, 2 , suggestive association signals in well-powered GWAS such as this one can substantially improve knowledge of disease architecture with a only modest penalty implied by the 5% FDR threshold. We have demonstrated the potential value of the new list of variants associated at 5% FDR in improving the prediction of CAD risk and implicating new networks underlying CAD pathophysiology. This extended list of candidate genes provides a powerful resource for functional studies.
We note that, while this work was under review, a study was published also reporting associations of the HNF1A locus with CAD 22 . URLs. UK Biobank, http://www.ukbiobank.ac.uk/; GWAS catalog, https://www.ebi.ac.uk/gwas/; GTEx portal, http://www.gtexportal.org/ home/; PhenoScanner, http://www.phenoscanner.medschl.cam.ac.uk/; Ingenuity Knowledge Base, https://www.qiagenbioinformatics.com/ products/ingenuity-pathway-analysis/; genotyping and quality control of UK Biobank, https://biobank.ctsu.ox.ac.uk/crystal/docs/genotyping_ qc.pdf; INDI-V calculator, http://cnsgenomics.com/shiny/INDI-V/; DEPICT, http://www.broadinstitute.org/mpg/depict.
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Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. Figure 4 Heat map showing DEPICT gene set enrichment results with zoom-in on a subset of the results. 556 gene sets were included that had evidence of enrichment at 1% FDR. The x axis shows the names of genes predicted to be included in the reconstituted gene sets shown along in the y axis. Red indicates higher z score, where z score is a value corresponding to a gene's inclusion in a reconstituted gene set. Clustering was performed on the basis of the complete linkage method. Highlighted pathways in the cluster include angiogenesis, blood vessel development and morphogenesis.
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Phenotype definitions and power calculation. UKBB recruited 502,713 individuals aged 40-69 years from England, Scotland and Wales between 2006 and 2010 (94% of self-reported European ancestry). HARD CAD was defined as fatal or nonfatal MI, PTCA or CABG. SOFT CAD included all HARD CAD as well as chronic ischemic heart disease (IHD) and angina. Controls were defined as individuals who were not a SOFT case after exclusions (listed below). All conditions were defined by either self-reported (questionnaire), hospital episode or death registry data. Exclusions were made for aneurysm and atherosclerotic cardiovascular disease using hospital admissions or cause of death codes ICD9 414.1 and ICD 10 I25.0, I25.3 and I25.4.
Susceptibility effect sizes in MI cases and an inclusive CAD definition were very similar to those in the earlier GWAS 2 . We hypothesized that the detailed clinical information in UKBB might enhance the search for new loci by further broadening the CAD phenotype to increase sample size.
GWAS and meta-analyses. All participants gave written consent for participation in genetic studies, and the protocol of each study was approved by the corresponding local research ethics committee or institutional review board. Participating cohorts in the 1000 Genomes and Exome GWAS studies are described elsewhere 2, 3 . UKBB samples were excluded due to withdrawn consent, sex mismatches (n = 182), Biobank/BiLEVE quality control exclusions (n = 406) and sample relatedness (n = 3,481) determined as kinship > 0.088. GWAS analysis in UKBB was restricted to variants with results available in the published GWAS 2 or Exome 3,4 data set. Further exclusions included poorly imputed (info < 0.4) or monomorphic variants, duplicate variants across data sets, variants that deviated strongly from Hardy-Weinberg equilibrium in European-ancestry controls (P < 1 × 10 −9 ), variants with an effect allele frequency in European-ancestry samples that differed strongly (i) from the 1000 Genomes European panel, (ii) from GWAS and/or Exome data, (iii) between arrays (UKBB versus UK-BiLEVE), and (iv) across genotyping batches. Variants that did not produce a valid result or estimated extreme log ORs (|β| > 4) were also excluded after analysis. Cluster plots of lead variants and proxies were visually inspected.
We ran the GWAS under an additive frequentist mode of inheritance for each variant using the dosages from the imputed data, adjusting for array (UK Biobank versus UK BiLEVE) and the first five principal components (see URLs) using SNPTEST. We did not adjust for age and sex to maximize the power to detect associations with diseases that have a prevalence <10% (ref. 23) . Population stratification was assessed and standard errors were adjusted using the genomic inflation statistic (λ).
Association summary statistics (after λ correction) from the UKBB were combined with the 1000 Genomes-imputed GWAS results 2 and the Exome results 3 via two separate fixed-effect inverse-variance-weighted meta-analyses implemented in GWAMA 24 . We applied post-meta-analysis λ correction in each instance. We identified 36,460 variants present in both the 1000 Genomes-imputed GWAS and Exome results. We retained the variants from the 1000 Genomes-imputed GWAS if the median info score was 1; otherwise we retained the results from the Exome data.
Comparison of SOFT versus HARD peak variant lists at a 5% q value.
The FDR following the meta-analysis with UKBB was assessed using a stepup procedure in the qqvalue Stata program 25 , as it is well controlled under positive regression-dependency conditions. We used the Simes method to generate q values for the 8.9 million variants. The P-value cutoff for a q value of 5% for HARD was 7.24 × 10 −5 and for SOFT was 6.28 × 10 −5 . Peak SNPs were identified in a 1-cM window. There was an exact overlap of 155 variants between the two peak variant lists; however, using the 1-cM window, the overlap increased to 206 variants. Both lists were annotated and classified into six categories (exome chip, indels, OR > 1.05, P < 5 × 10 −8 , MAF < 5% and exonic). The proportions were calculated in each of the six categories and plotted as a radar plot (Fig. 1b) . Monte Carlo simulations were used to assess the post hoc power of the UKBB interim data to replicate the 155 variants. The 1000 Genomes GWAS effect sizes ('betas') are expected to be subject to winner's curse inflation and so were shrunken (toward the null) by application of the FIQT procedure 26 . Effect sizes for firmly established CAD loci were systematically lower for the SOFT than for the HARD phenotype (Supplementary Table 1) ; we note that HARD closely corresponds to the CAD phenotype in ref. 2 . β values were therefore further shrunken by a factor log(1.059)/log(1.072) = 0.82 (Supplementary Table 1) . 10,000 replicates were then randomly drawn from the vector of shrunken β values and the corresponding UKBB standard errors to allow for variation in genotype call rates, imputation quality and allele frequency and to calculate Wald association statistics. Multiple testing of 155 variants was allowed for by controlling the FDR to 5% with a step-up procedure encoded in the multproc 27 Stata program. The average expected number of replicated variants was 56 (95% CI = 42-69). Testing the 5% FDR variants (Supplementary Table 7) in UKBB with a model adjusted for age and sex gave concordant results to the unadjusted model (data not shown).
GCTA and heritability analysis. We used GCTA software 7 to perform joint association analysis in (SOFT) meta-analysis results. This approach fits an approximate multiple regression model using summary-level meta-analysis statistics and LD corrections estimated from a reference panel (here, the UKBB sample). We adopted a chromosome-wide stepwise selection procedure to select variants and estimate their joint effects at (i) a genome-wide significance level (P joint ≤ 5 × 10 −8 ) in the totality of the meta-analyzed variants (n ~ 9 million; Supplementary Fig. 10 and Supplementary Table 11 ) and (ii) Bonferroni-corrected P joint < 1 × 10 −4 corresponding to the number of independent LD bins (r 2 < 0.1) in the 5% FDR variant list (n = 11,427; Supplementary Table 6) .
Heritability calculations were based on a multifactorial liability threshold model, implemented in the INDI-V 28 calculator (see URLs), under the assumption of a baseline population risk (K) of 0.0719 (ref. 29 ) and twin heritability (h L 2 ) of 0.4. Multiple regression estimates from the GCTA joint association analysis were used to estimate heritability for the 304 independent CAD risk variants within the 5% FDR list.
functional variants will have C score >10, and the top 1% of variants will have C score >20. Genome-wide annotation of variants (GWAVA) 36 19, 39 . Input to our analysis were the 11,427 CAD variants (FDR 5%), of which 11,311 were annotated in DEPICT. We constructed loci with DEPICT beta version 1.1, release 194 (see URLs). Analysis was performed with default parameters (50 repetitions to compute FDRs, 500 permutations to adjust for biases, such as gene length). The 11,311 variants were collapsed to 288 loci that were used in the gene set enrichment analyses. Correlated gene sets were grouped together based on gene membership to expedite data interpretation.
Ingenuity. Genes were selected using 304 independent SNPs (5% FDR) based on eQTLs (Supplementary Table 9 ) and physical proximity (included overlapping genes on opposite strands or at equal distance from the SNP). Spliced ESTs and putative transcripts were not included. Network analysis was performed using Ingenuity Pathway Analysis software (see URLs). We considered molecules and or relationships available in the IPA Knowledge Base for human or mouse or rat and set the confidence filter to 'experimentally observed or high' (predicted). Networks were generated with a maximum size of 70 genes, and up to ten networks were allowed. Networks are ranked according to their degree of relevance to the 'eligible' molecules in the query data set. The network score is based on the hypergeometric distribution and is calculated with the right-tailed Fisher's exact test. The significance P value associated with enrichment of functional processes is calculated using the right-tailed Fisher's exact test by considering the number of query molecules that participate in that function and the total number of molecules that are known to be associated with that function in the Ingenuity Knowledge Base.
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Data exclusions
Describe any data exclusions. UK Biobank (UKBB samples) were excluded due to withdrawn consent, sex mismatches (n=182), Biobank/Believe QC exclusions (n=406) and sample relatedness (n=3,481) determined as Kinship>0.088
Replication
Describe whether the experimental findings were reliably reproduced. All statistical analyses were ran in duplicate (different analysts) and results were checked for consistency. Replication in independent studies was undertaken for reporting CAD risk signals at the genome-wide level of significance
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
A brief description of each study is provided in the Supplementary Note along side the corresponding publication
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
N/A
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
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Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly.
A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
